Select Page

South Delhi Pharma, New Delhi, India

STIVARGA (regorafenib) tablets, oral

(2 customer reviews)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Stivarga (Regorafenib)

Product: STIVARGA (regorafenib) tablets, oral
Initial U.S. Approval: 2012
Indication: metastatic colorectal cancer (CRC)
Strength: 40 mg film-coated tablets
Company Bayer HealthCare Pharmaceuticals Inc.

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Stivarga (Regorafenib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Stivarga (Regorafenib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

What Stivarga is?

STIVARAG is a kinase inhibitor indicated for the treatment of patients with:

  • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
  • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
  • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

What Regorafenib is?

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers.

Pharma Services and Drug Inquiries

Our Pharma Division deals only with the best, GMP certified generics and branded medication for the export market. All our products are supported by strict adherence to quality and analysis certification.

Please note for the minimum order for Exports is of US$ 300. All orders will be subject to courier charges and supplies are normally dispatched through internationally accredited courier services.

Complete the form below to receive the no-obligation price quote.

Disclaimer

Note : We do not supply schedule-H (Example – narcotic drug or psychotropic drugs or anabolic steroids) and Anti- Abortion Drugs.

2 reviews for STIVARGA (regorafenib) tablets, oral

  1. Anton

    coursework writing service uk coursework topics coursework writing help coursework format

  2. Christy

    coursework masters vs research masters differential equations coursework coursework references coursework average calculator

Add a review

Your email address will not be published. Required fields are marked *